Johnson & Johnson’s Sirturo Gains the CHMP’s Positive Opinion to Treat Multidrug-Resistant Tuberculosis 

Shots: 

• The CHMP has granted positive opinion to the company’s Sirturo (bedaquiline) and recommended approving its Type II variation plus transitioning its conditional marketing authorization into a standard marketing authorization 

• The opinion was based on the data from P-III (STREAM) stage 2 trial assessing the safety & efficacy of bedaquiline-containing regimen to treat MDR-TB, depicting improvement and confirming its positive risk-benefit  

• Additionally, Sirturo received the US FDA’s accelerated approval in Dec 2012 & the EMA’s conditional approval in Mar 2014 based on the P-II study results. Its sNDA, submitted to the US FDA in Aug 2023, is underway for full approval 

Ref: Johnson & Johnson | Image: Johnson & Johnson| Press Release

Related News:- Johnson & Johnson’s Opsynvi (macitentan and tadalafil) Receives the US FDA’s Approval for the Treatment of Pulmonary Arterial Hypertension 

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com